|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase III Chemotherapy with AZQ vs BCNU in Adult Patients with Malignant Tumors of the Central Nervous System
(Summary Last Modified 06/97)
Basic Trial Information
Objectives I. Compare survival rates after therapy with either diaziquone or carmustine as initial drug therapy in patients with primary tumors of the central nervous system. II. Determine the rate and duration of response to therapy with either diaziquone or carmustine in patients with malignant primary tumors of the central nervous system. III. Compare the tolerance and toxicity of both drugs in these patients. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients between the ages of 18 and 80 with histologically proven Grade III/IV astrocytoma (glioblastoma multiforme) who have failed or who are not considered candidates for surgery and/or radiotherapy. Disease must be measurable. Prior chemotherapy excludes, and patients must be on stable or decreasing doses of maintenance steroids. At least 6 weeks must have elapsed since prior radiotherapy (unless there is evidence of tumor progression during or after radiotherapy, documented by successive CAT scans performed at least 2 weeks apart). There must be recovery from prior radiotherapeutic toxicity, i.e., absolute granulocyte and platelet counts must be greater than 1,500 and 150,000/cumm, respectively. A life expectancy of more than 4 weeks and adequate hepatic and renal function are required. Patients who require concurrent systemic chemotherapy with other agents, intracavitary/intrathecal chemotherapy, or radiotherapy are excluded as are those with more than one primary malignancy and those with other neurologic illnesses (e.g., dementia, multiple sclerosis, amyotrophic lateral sclerosis) that would obscure the evaluation of therapy. Pregnant and lactating females are ineligible. Expected Enrollment 110 patients will be entered per arm over approximately 3 years. Outline Randomized study. Arm I: Single-agent Chemotherapy. Diaziquone, Aziridinylbenzoquinone, AZQ, NSC-182986. Arm II: Single-agent Chemotherapy. Carmustine, BCNU, NSC-409962. Trial Lead Organizations Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |